anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aims and objectives: This study was performed to compare the effect of white noise, facilitated tucking, and their concerted application during heel-stick sampling on pain in term babies.

Design: A randomised clinical trial in a single centre. Methods: The study sample size was determined by the free-software G\* Power. Based on the power analysis performed prior to the study in order to determine the number of babies to be included in the sample group (with β=0.14087 and α=0.05 risk, Power=0.85913), according to the study by Karakoc and Turker (2014), it was found that 27 neonates should be included in each group. The study was conducted on 90 babies, between July 1, 2017 - August 9, 2017. Using stratification and blocking method, 30 babies were included in the white noise group (1st Group), 30 in facilitated tucking group (2nd Group), and 30 in white noise + facilitated tucking group (3rd Group). Pain scores of the babies in all groups before, during, and after the procedure were evaluated by two nurses independent from each other using Neonatal Infant Pain Scale (NIPS).
This investigation assessed associations between dietary carotenoid intake and the odds of overweight/obesity, as well as inflammatory/oxidative stress biomarkers, in 851 participants with overweight/obesity (BMI ≥25 kg m-2) and 754 normal-weight controls. A 124-item food-frequency-questionnaire (FFQ) and food composition databases were employed to estimate carotenoid intake. Binary logistic regressions assessed the association of carotenoid intake with the odds of overweight/obesity, adjusting for several potential confounders. Multiple linear regression models revealed associations between carotenoid intake and biomarkers (anthropometrics, blood lipids, inflammation, antioxidant status). Logistic regression models adjusted for various confounders and fruits and vegetables showed protective associations for provitamin A carotenoids (i.e., β-carotene + α-carotene + β-cryptoxanthin; odds ratio (OR): 0.655, p = 0.041) and astaxanthin (OR: 0.859, p = 0.017). Similarly adjusted multiple linear regressions revealed significant associations between several carotenoids and lower levels of interleukin (IL)-6, IL-1β, and TNF-α and increased IL-10 and total antioxidant capacity. Further analysis revealed that lycopene was significantly associated with increased odds of overweight/obesity (OR: 1.595, p = 0.032) in a model adjusted for various confounders and vegetables (i.e., unadjusted for fruits). A protective association between the sum of provitamin A carotenoid and astaxanthin dietary intake and the odds of having overweight/obesity was found. The findings that carotenoids other than lycopene were not or inversely associated with the odds of overweight/obesity may point toward differentiating effects of various carotenoids or their associations with different food groups. Provitamin A rich food items including fruits and vegetables appear to be a prudent strategy to reduce inflammation and the odds of having overweight/obesity.
PROBLEM TO BE SOLVED: To obtain an O/W-type emulsion composition capable of introducing a wax into the O/W-type emulsion at a high ratio while keeping sufficient fluidity and comfortable feeling to the skin in application by including a mixture of a nonionic emulsifying agent. SOLUTION: The objective emulsion has the form of an O/W-type emulsion containing an oil phase dispersed in a water phase and contains a mixture of at least two kinds of nonionic emulsifying agent. The mixture is liquid at normal temperature, has an HLB value of 6-13 and contains one or more waxes in the oil phase in an amount of >=5 wt.% based on the total weight of the composition. At least one kind of the wax has a dissolution starting temperature of >=50 deg.C. The emulsifying agent mixture preferably contains (A) at least one kind of nonionic emulsifying agent having an HLB of >=13 and (B) at least one kind of nonionic emulsifying agent having an HLB of <=5. The emulsifying agent mixture preferably further contains at least one kind of coemulsifying agent.
Participants will apply tirbanibulin ointment 1% once daily for 5 days beginning Day 1. Participants will be evaluated for safety, tolerability, and the presence of Actinic Keratosis (AK) lesions in the treatment field (TF) until completion of the response assessment period at Day 57.
The advent of chimeric antigen receptor T cells (CAR-T) has been a paradigm shift in cancer immunotherapeutics, with remarkable outcomes reported for a growing catalog of malignancies. While CAR-T are highly effective in multiple diseases, salvaging patients who were considered incurable, they have unique toxicities which can be life-threatening. Understanding the biology and risk factors for these toxicities has led to targeted treatment approaches which can mitigate them successfully. The three toxicities of particular interest are cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and immune effector cell-associated hemophagocytic lymphohistiocytosis (HLH)-like syndrome (IEC-HS). Each of these is characterized by cytokine storm and hyperinflammation; however, they differ mechanistically with regard to the cytokines and immune cells that drive the pathophysiology. We summarize the current state of the field of CAR-T-associated toxicities, focusing on underlying biology and how this informs toxicity management and prevention. We also highlight several emerging agents showing promise in preclinical models and the clinic. Many of these established and emerging agents do not appear to impact the anti-tumor function of CAR-T, opening the door to additional and wider CAR-T applications.
Central venous catheters are commonly used for vascular access in the hemodialysis population. A common complication is low / no blood flow through the catheter due to clots. These are serious situations because patients may miss dialysis sessions and suffer significant morbidity. In an attempt to dissolve the clots and restore blood flow, thrombolytics are frequently instilled into the catheters between dialysis sessions . However, we have developed and new "push" protocol that advances fresh thrombolytic (alteplase) to the tip of the catheter in order to facilitate more effective and faster removal of the clot. We hypothesize that our new "push" protocol will dissolve clots in hemodialysis catheters better and faster than the current dwell method.
The invention discloses a method for countercurrent ultrasonic extraction of active ingredients from traditional Chinese medicine salvia miltiorrhiza. The method includes the following steps: (1) adding the salvia miltiorrhiza into 3-5 extraction pots which are sequentially arranged, wherein one part is added in each extraction pot; (2) adding 3 parts of ethanol solution with the volume fraction being 85%-95% for the countercurrent ultrasonic extraction for the first time; (3) adding 3 parts of the ethanol solution with the volume fraction being 50% for the countercurrent ultrasonic extraction for the second time; and (4) adding 5 parts of water for the countercurrent ultrasonic extraction for the third time. The extraction needs to be conducted twice for each time. After being filtered, the primary extraction solution is placed into a liquid storage pot, and secondary extraction solution enters a subsequent or a previous extraction pot so as to be used as solvent of the extraction at a time. The method for the countercurrent ultrasonic extraction of the active ingredients from the traditional Chinese medicine salvia miltiorrhiza is applied to the extraction of the active ingredients from the salvia miltiorrhiza in the production process of traditional Chinese medicine compound salvia miltiorrhiza tablets, and the extraction solution is high in the content of fat soluble and water soluble active ingredients. By the means of the method for the countercurrent ultrasonic extraction of the active ingredients from the traditional Chinese medicine salvia miltiorrhiza, the extraction efficiency is enhanced, natural resources of Chinese medicine materials are saved and the labor efficiency is improved.
H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed and the result show that H. pylori is not eradicated.
Colorectal cancer is associated with iron deficiency anaemia in 40-60% of cases. This anaemia can lead to poorer post-operative outcomes such as higher complication rates, increased length of stay and reduced survival. There has been a recent shift towards the correction of preoperative anaemia in order to optimize perioperative outcomes. However, despite improvements in preoperative haemoglobin there exists a group of patients who develop worsening or recurrent anaemia in the post-operative period. Without intervention up to 90% of patients in the immediate postoperative period may develop anaemia. This is not unexpected given the peri-operative blood loss; poor nutritional intake in the postoperative period; and the frequent blood sampling for laboratory tests. Our data from previous trials has demonstrated that despite preoperative intravenous iron therapy 75% of patients remain anaemic at the time of their colorectal cancer operation. In addition, our unpublished data has found that around 1/3 of patients treated with preoperative iron therapy develop a recurrence of their anaemia in the first year postoperatively. Studies have identified that traditional oral ferrous iron supplementation is largely ineffective for the treatment of postoperative anaemia. However, a newer oral iron preparation - ferric maltol (Ferracru) has been found to be better tolerated and more efficacious than ferrous iron. This study aims to evaluate whether the use of iron supplementation in the form of Feraccru could lead to a more sustained or improved a response in haemoglobin if given after a colorectal cancer operation. Improving this postoperative anaemia may have important implications for clinician and patient reported outcomes. The Perioperative Iron in Colorectal Cancer (PICoC) trial will run as a feasibility study to assess the proposed design, recruitability and outcome measures. Anaemic colorectal cancer patients treated with preoperative intravenous iron will be randomised in an open label design to receive a course of Ferric maltol (intervention group) or standard care (control group) postoperatively. Secondary outcome measures will focus on a comparison of change in blood indices, quality of life, allogenic red blood transfusion rates and postoperative complications between groups. Follow up will continue until the first postoperative outpatient visit at approximately 12 weeks following discharge.
Although the incidence of the adenocarcinoma of the stomach is slowly decreasing, gastric cancer represents the second worldwide cause of cancer death after lung cancer. In patients with advanced disease, chemotherapy improves survival and quality of life. Combinations of two or three drugs including a platin derivative (cisplatin or oxaliplatin), a fluoropyrimidine (5FU or capecitabine) and an anthracycline (usually epirubicin) have demonstrated superiority compared to single or double agent therapy and are the current standard. As of today there are no published studies comparing anthracycline-based to taxane-based three-drug regimens. The objective of the present study is to compare EOX as evaluated in REAL-2 to the low-TOX regimen consisting of docetaxel, oxaliplatin and capecitabine. Low-TOX is expected to be better tolerated than the original DCF regimen. The study will be performed in the HER2 negative patients.
Q. Hair Regrowth Spray (Q. Hair Spray) is a combination of Dried Lavender, Dried Rosemary, Chopped Ginger, Dried Sage, Evaporated Cane Juice, Soybean oil, Extra Virgin Olive Oil, and Citric Acid boiled in distilled water. The combination of these ingredients suppresses Dihydrotestoserone , reopens the hair follicles and allows the papilla to grow hair again. This treats multiple forms of Alopecia. Q. Hair Regrowth Spray (Q. Hair Spray) allows the hair to grow back from bald and thin areas on the scalp. This was created by Dr. Levy Q. Barnes, Jr
The Frozen Shoulder is a frequently encountered pathology in clinical practice. This condition often coexists with various comorbidities and is characterized by severe pain and a significantly restricted motion of the affected shoulder. A limited passive external rotation with the arm in adduction, with no signs of any other pathology that could explain the finding, such as shoulder osteoarthritis or an undetected posterior dislocation, is pathognomonic. The course of the disease typically spans over one to two years and is usually self-limiting. In the vast majority of cases, this condition can be managed conservatively. Keywords: shoulder, shoulder stiffness, shoulder pain, conservative therapy.
Metformin will be administered to participants as a single oral dose on Day 1 and then co-administered with VX-993 on Day 10. VX-993 dose will be administered every 12 hours (q12h) from Day 5 through Day 14.
Women randomized to receive three 800 mcg doses of misoprostol taken sublingually in three hour intervals. All women receive a semi-quantitative pregnancy test for at-home follow up.
Tiotropium 18 μg once a day and placebo to NVA237 once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
Euphorbia hirta L. plants and their extracts and active ingredients can be used to increase the immunity of the human body and as an antifungal agent to treat open wounds. The extracts are obtd. from the leaves and/or stems of Euphorbia hirta L. and are aq. or aq./alcoholic. The agent is in the form of a tea made from Euphorbia hirta L. The active ingredients are flavonoids, polyphenols, sterols and/or triterpenes. USE/ADVANTAGE - The resistance of the human body against pathogenic organisms, esp. those which cause infection and their metabolic prods., e.g., toxins, is increased, i.e. the immune system is stimulated. Thus the invention can be used to stimulate the immune system against flu, winter colds and AIDS. The invention can also be used as an antifungal agent to treat open wounds.
One of the non-pharmacological methods used in pain management is Transcutaneous Electrical Nerve Stimulation (TENS). Nurses play an important role in patient follow-up after surgery. It also has the responsibility to administer analgesics with the least side effects and the most effect. The New York Association of Nurses states that TENS is a complementary treatment method and its application strengthens the professional independence of nurses. However, as a result of our studies and observations, it is seen that there is no protocol for the use of TENS after thoracic surgery. TENS is applied together with physicians according to the nursing regulations in Turkey. Postoperative pain management requires team collaboration. Therefore, nurses should play a key role in pain management and use non-pharmacological methods.
The Rab family of guanosine triphosphatases (GTPases) includes key regulators of intracellular transport and membrane trafficking targeting specific steps in exocytic, endocytic, and recycling pathways. DENND5B (Rab6-interacting Protein 1B-like protein, R6IP1B) is the longest isoform of DENND5, an evolutionarily conserved DENN domain-containing guanine nucleotide exchange factor (GEF) that is highly expressed in the brain. Through exome sequencing and international matchmaking platforms, we identified five de novo variants in DENND5B in a cohort of five unrelated individuals with neurodevelopmental phenotypes featuring cognitive impairment, dysmorphism, abnormal behavior, variable epilepsy, white matter abnormalities, and cortical gyration defects. We used biochemical assays and confocal microscopy to assess the impact of DENND5B variants on protein accumulation and distribution. Then, exploiting fluorescent lipid cargoes coupled to high-content imaging and analysis in living cells, we investigated whether DENND5B variants affected the dynamics of vesicle-mediated intracellular transport of specific cargoes. We further generated an in silico model to investigate the consequences of DENND5B variants on the DENND5B-RAB39A interaction. Biochemical analysis showed decreased protein levels of DENND5B mutants in various cell types. Functional investigation of DENND5B variants revealed defective intracellular vesicle trafficking, with significant impairment of lipid uptake and distribution. Although none of the variants affected the DENND5B-RAB39A interface, all were predicted to disrupt protein folding. Overall, our findings indicate that DENND5B variants perturb intracellular membrane trafficking pathways and cause a complex neurodevelopmental syndrome with variable epilepsy and white matter involvement.
Infested household participants will administer a single application of up to 117 grams (1 tube) of generic ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
The present invention relates to the delivery of erectile dysfunction drugs through an inhalation route. Specifically, it relates to aerosols containing erectile dysfunction drugs that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an erectile dysfunction drug. In a method aspect of the present invention, an erectile dysfunction drug is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an erectile dysfunction drug, to form a vapor; and, b) allowing th e vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an erectile dysfunction drug through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an erectile dysfunction drug; and, b) a device that for ms an erectile dysfunction drug aerosol from the composition, for inhalation by the mammal.
We report a case of extramedullary plasmacytoma of the larynx that was eradicated by radiotherapy; however, 8 years later, the disease had progressed to multiple myeloma. A mid -60s Japanese woman presented with a right-sided arytenoid mass in the larynx who underwent biopsy at another hospital. Based on the biopsy results, the patient was diagnosed with extramedullary plasma cell tumour and was referred to the Department of Otorhinolaryngology at our hospital. She received radiotherapy (50.4 Gy) and the laryngeal tumour was eradicated. Positron emission tomography/CT (PET-CT) revealed no abnormal accumulation in the larynx or whole body. After radiotherapy, the department of otorhinolaryngology, in consultation with Ddepartment of haematology performed follow-ups using laryngoscope, blood examination and PET-CT. Five years after the end of radiotherapy, the patient had no local recurrence or transition to multiple myeloma. However, 8 years later, blood examination and PET-CT revealed multiple myeloma. Laryngoscopy did not reveal any recurrent laryngeal tumour. Therefore, chemotherapy for multiple myeloma was administered at the department of haematology. Three months after the initiation of chemotherapy, the accumulation had disappeared in PET-CT. Three years have passed since chemotherapy initiation. At present, no recurrence or metastasis was observed in the larynx or whole body.
A process is disclosed for producing moulded, pressed dose units with retarded release of a therapeutic active ingredient having compression pressure dependent self-retarding properties. In order to produce dose units having a very uniform. essentially linear and reproducible constant release of the active ingredient, the active ingredient is reduced during a first step to particles. with a fraction of an additive that inhibits or compensates its self-retarding properties. so that mouldings formed with these particles with no further additives have a rapid release in relation to the desired retarded release in the pressure range required to compress the dose units. Then, during a second step. the particles are moulded with a retardant into dose units. Corresponding dose units are also disclosed.
The user should wear waterproof gloves during the entire procedure and while withdrawing the patient dose from the NeutroSpecTM vial.

Transfer Sodium Pertechnetate Tc 99m Injection, USP with an adequately shielded, sterile syringe.

Adequate shielding should be maintained at all times until the preparation is administered to the patient, disposed of in an approved manner, or allowed to decay to background levels. A shielded, sterile syringe should be used to withdraw and inject the labeled preparation.

Before reconstituting a vial, it should be inspected for cracks and any indication that the integrity of the vacuum seal has been lost. The material should not be used if integrity of the vacuum seal has been lost. After reconstitution, examine the vial contents for particulates and discoloration prior to injection. The material should not be used if particulates or discoloration are observed.

The dose should be injected via an indwelling catheter, butterfly, or equivalent injection system to assure that no dose infiltration occurs. Following administration, flush the injection line with an appropriate volume of saline to assure administration of the total dose.
Subjects will be asked to use one spray in one nostril 4 times daily (9AM, 1PM, 5PM and 9 PM). Subjects will take 4 sprays daily of oxytocin for the entire study.
PURPOSE:To obtain a sustained release preparation capable of controlling a bursting time of a film and retaining pharmacodynamic effects for a long time by adding a sufficient amount of a swelling agent and a water-insoluble coating substance to FK739 substance. CONSTITUTION:This preparation contains FK739 substance having a pharmacological activity such as angiotensin II antagonism as a main medicine or its salt, a swelling agent (e.g. hydroxypropylcellulose having low substitution degree) and a water-insoluble coating substance (e.g. ethyl cellulose). This swelling agent is included in an amount enough to burst a film by the swelling agent swollen by water content after the lapse of a prescribed time, normally in an amount of 10-80% based on the preparation. Since elution of FK737 substance is controlled by bursting of the film, the elution rate and elution pattern of the FK737 substance are not influenced on solubility and elution rate of the FK739 substance itself, unlike conventional diffusion control or elution control. The elution rate and pattern of the FK739 substance do not depend on pH change of digestive juice. Further, this preparation is a sustained release preparation capable of completely eluting the FK739 substance from the preparation.
The control group does reformer pilates for 45 minutes 3 days a week. The intensity of the workouts was gradually increased. Warm-up (10 minutes), main Pilates training activity (25 minutes), and cool-down (10 minutes) were the three parts of each session (10 minutes). Individuals in the CG received no dietary or nutritional intervention. On any diet, the status of women in the CG was frequently questioned.